SG166817A1 - Platelet aggregation inhibitor composition - Google Patents

Platelet aggregation inhibitor composition

Info

Publication number
SG166817A1
SG166817A1 SG201008077-8A SG2010080778A SG166817A1 SG 166817 A1 SG166817 A1 SG 166817A1 SG 2010080778 A SG2010080778 A SG 2010080778A SG 166817 A1 SG166817 A1 SG 166817A1
Authority
SG
Singapore
Prior art keywords
amino acid
acid sequence
polypeptide
platelet aggregation
inhibitory activity
Prior art date
Application number
SG201008077-8A
Other languages
English (en)
Inventor
Shigeto Yoshida
Toshiki Sudo
Original Assignee
Educational Foundation Jichi M
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Educational Foundation Jichi M, Otsuka Pharma Co Ltd filed Critical Educational Foundation Jichi M
Publication of SG166817A1 publication Critical patent/SG166817A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
SG201008077-8A 2005-11-04 2006-11-02 Platelet aggregation inhibitor composition SG166817A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005320817 2005-11-04

Publications (1)

Publication Number Publication Date
SG166817A1 true SG166817A1 (en) 2010-12-29

Family

ID=38005983

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201008077-8A SG166817A1 (en) 2005-11-04 2006-11-02 Platelet aggregation inhibitor composition

Country Status (19)

Country Link
US (2) US8034763B2 (ru)
EP (2) EP2077328B1 (ru)
JP (1) JP4954204B2 (ru)
KR (1) KR101311570B1 (ru)
CN (2) CN102911264B (ru)
AR (1) AR057858A1 (ru)
AU (1) AU2006309543B2 (ru)
BR (1) BRPI0618194A2 (ru)
CA (1) CA2625106C (ru)
ES (2) ES2547404T3 (ru)
HK (1) HK1120074A1 (ru)
IL (2) IL188986A0 (ru)
MY (1) MY148135A (ru)
PH (1) PH12013502021A1 (ru)
RU (2) RU2434941C2 (ru)
SG (1) SG166817A1 (ru)
TW (1) TWI391143B (ru)
WO (1) WO2007052841A1 (ru)
ZA (1) ZA200801161B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108503692B (zh) * 2017-07-10 2019-12-31 昆明医科大学第一附属医院 一种促血小板聚集的多肽pep1
CN108503689B (zh) * 2017-07-10 2019-12-31 昆明医科大学第一附属医院 一种抗血小板聚集的多肽km6
CN110339344B (zh) * 2019-08-07 2022-12-30 上海交通大学医学院附属仁济医院 核受体Rev-erbα在制备抗血小板药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2143416C (en) * 1993-07-01 2003-06-10 Jurgen Hemberger Inhibitor of collagen-stimulated platelet aggregation
NZ293261A (en) * 1994-09-12 1998-11-25 Schering Ag Recombinant pallidipin protein, asp-pallidipin, which inhibits collagen induced platelet aggregation inhibitor
RU2192857C1 (ru) * 2001-04-24 2002-11-20 Институт органической химии им. Н.Д. Зелинского РАН Ингибитор агрегации тромбоцитов, обладающий антиметастатическим действием
JP3648548B2 (ja) * 2001-10-15 2005-05-18 国立大学法人三重大学 血液凝固阻害活性を有するハマダラカ由来のＡｓ−１蛋白質
JP3837518B2 (ja) 2002-10-02 2006-10-25 国立大学法人三重大学 血小板凝集阻害活性を有するブラジルサシガメ由来のＴｉ−４蛋白質
JP3837519B2 (ja) 2002-10-02 2006-10-25 国立大学法人三重大学 血小板凝集阻害活性を有するブラジルサシガメ由来のＴｉ−３蛋白質

Also Published As

Publication number Publication date
IL228986A0 (en) 2013-12-31
MY148135A (en) 2013-02-28
RU2008122338A (ru) 2009-12-10
CN101273128B (zh) 2012-11-21
US20120004186A1 (en) 2012-01-05
ES2547404T3 (es) 2015-10-06
KR101311570B1 (ko) 2013-09-26
TW200735887A (en) 2007-10-01
JP2009514785A (ja) 2009-04-09
AU2006309543B2 (en) 2012-01-19
RU2434941C2 (ru) 2011-11-27
US20100004164A1 (en) 2010-01-07
RU2557296C2 (ru) 2015-07-20
HK1120074A1 (en) 2009-03-20
JP4954204B2 (ja) 2012-06-13
US8034763B2 (en) 2011-10-11
KR20080105024A (ko) 2008-12-03
PH12013502021B1 (en) 2015-12-14
CA2625106C (en) 2016-08-02
EP2077328B1 (en) 2015-07-15
CA2625106A1 (en) 2007-05-10
EP1943337A4 (en) 2008-12-03
US8309512B2 (en) 2012-11-13
EP1943337A1 (en) 2008-07-16
CN101273128A (zh) 2008-09-24
PH12013502021A1 (en) 2015-12-14
WO2007052841A1 (en) 2007-05-10
EP2077328A1 (en) 2009-07-08
AR057858A1 (es) 2007-12-19
CN102911264A (zh) 2013-02-06
IL188986A0 (en) 2008-08-07
ZA200801161B (en) 2009-08-26
EP1943337B1 (en) 2015-07-15
CN102911264B (zh) 2014-03-19
AU2006309543A1 (en) 2007-05-10
ES2547380T3 (es) 2015-10-05
BRPI0618194A2 (pt) 2011-08-23
RU2011120138A (ru) 2012-11-27
TWI391143B (zh) 2013-04-01

Similar Documents

Publication Publication Date Title
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
NZ600690A (en) Fkbp-l and uses thereof
HRP20090245T1 (en) Pyy agonists and uses thereof
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
EP1801206A4 (en) PROCESS FOR THE PREPARATION OF L-ARGININE, L-ORNITHIN OR L-CITRULLINE
WO2005023866A3 (en) Peptides that inhibit complement activation
IS2714B (is) Uppsöfnun í frumu á phosphomate hliðstæðum á HIV próteasa hindrandi efnasamböndum
MY138708A (en) Biaryloxymethylarenecarboxylic acids
WO2007002465A3 (en) Stabilizing alkylglycoside compositions and methods thereof
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
MY151973A (en) Cyclic depsipeptides
NZ586430A (en) Mutant forms of streptolysin o (slo)
NZ601592A (en) Recombinant elastase proteins and methods of manufacturing and use thereof
PH12013502021A1 (en) Platelet aggregation inhibitor composition
WO2005056577A3 (en) Peptide inhibitors of hiv
CA2549185A1 (en) Peptide inhibiting angiotensin converting enzyme
NZ589365A (en) Peptidyl diacylglycerides
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
HK1147210A1 (en) Anti-hypertensive agent
AU2002319236A1 (en) Method for the production of protamine
HK1131162A1 (en) Cytokine derivatives
GB0221169D0 (en) Crystal